GT200000194A - COMBINATION CHEMOTHERAPY. - Google Patents
COMBINATION CHEMOTHERAPY.Info
- Publication number
- GT200000194A GT200000194A GT200000194A GT200000194A GT200000194A GT 200000194 A GT200000194 A GT 200000194A GT 200000194 A GT200000194 A GT 200000194A GT 200000194 A GT200000194 A GT 200000194A GT 200000194 A GT200000194 A GT 200000194A
- Authority
- GT
- Guatemala
- Prior art keywords
- agents
- combination
- carboplatin
- paclitaxel
- compartment
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pain & Pain Management (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
LA INVENCION SE REFIERE A UN METODO PARA TRATAR TUMORES SOLIDOS AVANZADOS UTILIZANDO COMBINACIONES DE AGENTES ONCOLITICOS CONOCIDOS. EL USO DE LOS AGENTES JUNTOS PROPORCIONA INESPERADAMENTE UN EFICACIA MAYOR QUE SI SE EMPLEAN COMO AGENTES SIMPLES SOLAMENTE. HEMOS DESCUBIERTO UNA UNICA COMBINACION DE AGENTES ONCOLITICOS CONOCIDOS QUE EXHIBE UNA IMPORTANTE EFECTO SINERGETICO. LA COMBINACION UTILIZA EL AGENTE ACETILDINALINA, JUNTO CON PACLITAXEL Y/O CARBOPLATINA, EN UNA COMBINACION BINARIA O CON LOS TRES COMPONENTES SIMULTANEAMENTE. LA INVENCION COMPRENDE ADEMAS FORMULACIONES FARMACOLOGICAMENTE EFECTIVAS, TRATAMIENTOS, ADEMAS DE LA PRESENTACION EN UN COMPARTIMIENTO DE DOSIFICACION DE ACETIDINALINA Y EN OTRO COMPARTIMIENTO UNA DOSIFICACION DE CARBOPLATINA Y/O OTRO COMPARTIMIENTO DE DOSIFICACION DE PACLITAXEL. UNA COMBINACION DE AGENTES ANTINEOPLASICOS QUE COMPRENDEN UNA CANTIDAD ANTITUMOR DE ACETIDINALINA Y UNA CANTIDAD ANTITUMOR DE PACLITAXEL Y / O CARBOPLATINA. LA ACETILDINALINA EN COMBINACION CON PACLITAXEL Y / O CARBOPLATINA ES SINERGISTICA PARA TRATAR EL CANCER.THE INVENTION REFERS TO A METHOD FOR TREATING ADVANCED SOLID TUMORS USING COMBINATIONS OF KNOWN ONCOLITIC AGENTS. THE USE OF THE AGENTS TOGETHER PROVIDES UNFORGETTABLELY EFFECTIVENESS THAN IF USED AS SIMPLE AGENTS ONLY. WE HAVE DISCOVERED A UNIQUE COMBINATION OF KNOWN ONCOLITIC AGENTS THAT DISPLAYS AN IMPORTANT SYNERGETIC EFFECT. THE COMBINATION USES THE ACETILDINAL AGENT, TOGETHER WITH PACLITAXEL AND / OR CARBOPLATIN, IN A BINARY COMBINATION OR WITH THE THREE COMPONENTS SIMULTANEOUSLY. THE INVENTION ALSO INCLUDES PHARMACOLOGICALLY EFFECTIVE FORMULATIONS, TREATMENTS, IN ADDITION TO THE PRESENTATION IN AN ACETIDINALINE DOSAGE COMPARTMENT AND IN ANOTHER COMPARTMENT A CARBOPLATIN DOSAGE COMPARTMENT AND / OR ANOTHER PACL DOSAGE COMPARTMENT. A COMBINATION OF ANTINEOPLASIC AGENTS THAT INCLUDE AN ANTIBODY AMOUNT OF ACETIDINALINE AND AN ANTIBODY AMOUNT OF PACLITAXEL AND / OR CARBOPLATIN. ACETILDINALINE IN COMBINATION WITH PACLITAXEL AND / OR CARBOPLATIN IS SYNERGISTIC TO TREAT CANCER.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US16488999P | 1999-11-10 | 1999-11-10 | |
| US22256100P | 2000-08-03 | 2000-08-03 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| GT200000194A true GT200000194A (en) | 2002-05-03 |
Family
ID=26860956
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| GT200000194A GT200000194A (en) | 1999-11-10 | 2000-11-09 | COMBINATION CHEMOTHERAPY. |
Country Status (17)
| Country | Link |
|---|---|
| EP (1) | EP1229916A2 (en) |
| JP (1) | JP2003513912A (en) |
| KR (1) | KR20020060226A (en) |
| CN (1) | CN1387438A (en) |
| AR (1) | AR026400A1 (en) |
| AU (1) | AU1583201A (en) |
| CA (1) | CA2386876A1 (en) |
| GT (1) | GT200000194A (en) |
| HU (1) | HUP0203153A3 (en) |
| IL (1) | IL149363A0 (en) |
| NZ (1) | NZ518668A (en) |
| PA (1) | PA8506201A1 (en) |
| PE (1) | PE20011028A1 (en) |
| PL (1) | PL355170A1 (en) |
| SV (1) | SV2001000212A (en) |
| UY (1) | UY26431A1 (en) |
| WO (1) | WO2001034131A2 (en) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CZ20022216A3 (en) * | 2001-07-02 | 2003-05-14 | Warner-Lambert Company | Compound chemotherapy |
| PE20050206A1 (en) * | 2003-05-26 | 2005-03-26 | Schering Ag | PHARMACEUTICAL COMPOSITION CONTAINING AN INHIBITOR OF HISTONE DEACETILASE |
| CA2552279C (en) * | 2003-12-02 | 2014-07-15 | The Ohio State University Research Foundation | Zn2+-chelating motif-tethered short -chain fatty acids as a novel class of histone deacetylase inhibitors |
| US7951780B2 (en) | 2004-02-25 | 2011-05-31 | Astellas Pharma Inc. | Antitumor agent |
| EP2322217A3 (en) * | 2004-07-16 | 2011-09-28 | Pfizer Products Inc. | Combination treatment for non-hematologic malignancies using an anti-IGF-1R antibody |
| PL2415382T3 (en) | 2010-08-06 | 2013-02-28 | Electrolux Home Products Corp Nv | Table top dishwasher |
| EP3461480A1 (en) | 2017-09-27 | 2019-04-03 | Onxeo | Combination of a dna damage response cell cycle checkpoint inhibitors and belinostat for treating cancer |
| EP3461488A1 (en) | 2017-09-27 | 2019-04-03 | Onxeo | Combination of a dbait molecule and a hdac inhibitor for treating cancer |
| WO2021148581A1 (en) | 2020-01-22 | 2021-07-29 | Onxeo | Novel dbait molecule and its use |
| WO2023041805A1 (en) | 2021-09-20 | 2023-03-23 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for improving the efficacy of hdac inhibitor therapy and predicting the response to treatment with hdac inhibitor |
| WO2023194441A1 (en) | 2022-04-05 | 2023-10-12 | Istituto Nazionale Tumori Irccs - Fondazione G. Pascale | Combination of hdac inhibitors and statins for use in the treatment of pancreatic cancer |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ219974A (en) * | 1986-04-22 | 1989-08-29 | Goedecke Ag | N-(2'-aminophenyl)-benzamide derivatives, process for their preparation and their use in the control of neoplastic diseases |
-
2000
- 2000-11-03 JP JP2001536131A patent/JP2003513912A/en active Pending
- 2000-11-03 IL IL14936300A patent/IL149363A0/en unknown
- 2000-11-03 EP EP00978360A patent/EP1229916A2/en not_active Withdrawn
- 2000-11-03 AU AU15832/01A patent/AU1583201A/en not_active Abandoned
- 2000-11-03 CA CA002386876A patent/CA2386876A1/en not_active Abandoned
- 2000-11-03 PL PL00355170A patent/PL355170A1/en not_active Application Discontinuation
- 2000-11-03 HU HU0203153A patent/HUP0203153A3/en unknown
- 2000-11-03 KR KR1020027005970A patent/KR20020060226A/en not_active Application Discontinuation
- 2000-11-03 CN CN00815470A patent/CN1387438A/en active Pending
- 2000-11-03 NZ NZ518668A patent/NZ518668A/en unknown
- 2000-11-03 WO PCT/US2000/030377 patent/WO2001034131A2/en not_active Application Discontinuation
- 2000-11-07 SV SV2000000212A patent/SV2001000212A/en not_active Application Discontinuation
- 2000-11-09 PA PA20008506201A patent/PA8506201A1/en unknown
- 2000-11-09 UY UY26431A patent/UY26431A1/en not_active Application Discontinuation
- 2000-11-09 AR ARP000105899A patent/AR026400A1/en unknown
- 2000-11-09 GT GT200000194A patent/GT200000194A/en unknown
- 2000-11-09 PE PE2000001196A patent/PE20011028A1/en not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| WO2001034131A2 (en) | 2001-05-17 |
| AU1583201A (en) | 2001-06-06 |
| HUP0203153A2 (en) | 2003-01-28 |
| CN1387438A (en) | 2002-12-25 |
| IL149363A0 (en) | 2002-11-10 |
| PL355170A1 (en) | 2004-04-05 |
| PE20011028A1 (en) | 2001-10-12 |
| UY26431A1 (en) | 2000-12-29 |
| EP1229916A2 (en) | 2002-08-14 |
| AR026400A1 (en) | 2003-02-12 |
| SV2001000212A (en) | 2001-10-25 |
| NZ518668A (en) | 2004-04-30 |
| PA8506201A1 (en) | 2002-12-11 |
| KR20020060226A (en) | 2002-07-16 |
| WO2001034131A3 (en) | 2002-05-10 |
| JP2003513912A (en) | 2003-04-15 |
| HUP0203153A3 (en) | 2005-01-28 |
| CA2386876A1 (en) | 2001-05-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| UY28213A1 (en) | NEW CYANOPIRIDINE DERIVATIVES USEFUL IN THE TREATMENT OF CANCER AND OTHER DISORDERS. | |
| UY27943A1 (en) | COMPOSITIONS AND METHODS TO TREAT CRNCER USING ANTIBODY IMMUNOCATE PLAYS FOR CD44 CYTOTNXICS AND CHEMOTHERAPCUTIC AGENTS | |
| CL2008002224A1 (en) | Pharmaceutical composition comprising a) a compound selected from paclitaxel, docetaxel, ispinesib, thiazoloquinoline, among others, and b) aurora kinase inhibitor compounds selected from imidazopyrazine derivatives; use of combination and composition to treat cancer. | |
| CR8181A (en) | USE OF A COMBINATION OF AN INHIBITOR OF THE KINASA OF THE RECEIVER OF THE EPIDERMAL GROWTH FACTOR AND CYTOTOXIC AGENTS FOR THE TREATMENT AND INHIBITION OF CANCER | |
| DOP2012000290A (en) | 4-IODO-3-NITROBENZAMIDE IN COMBINATION WITH ANTI-TUMOR AGENTS FOR USE IN THE TREATMENT OF CANCER UTERO AND CANCER DE OVARIO | |
| AR048502A1 (en) | ANTI-CANCER COMPOUND THERAPEUTIC SYNERGY | |
| ATE538103T1 (en) | QUINAZOLINONE COMPOUNDS AS ANTICANCER AGENTS | |
| BRPI0506977A (en) | compound of tetrahydrocarboline as anticancer agents | |
| AR048819A1 (en) | SYNERGIC METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER | |
| UY28287A1 (en) | COMBINATIONS FOR THE TREATMENT OF DISEASES THAT IMPACT CELLULAR PROLIFERATION, MIGRATION OR APOPTOSIS OF MYELOMA CELLS, OR ANGIOGENESIS | |
| AR054094A1 (en) | CANCER TREATMENTS | |
| BRPI0612845A8 (en) | compound, pharmaceutical formulation, methods for treating cancer and for synthesizing a compound of formula | |
| WO2004030627A3 (en) | Synergistic methods and compositions for treating cancer | |
| CR7899A (en) | PROTEIN QUINASA INHIBITING TRICICLIC COMPOUNDS TO IMPROVE THE EFFECTIVENESS OF ANTIENOPLASTIC AGENTS AND DERIVATIVES OF DIAZENPAMDIONILO AS QUINASE INHIBITORS | |
| AR052774A1 (en) | IMMUNOTHERAPY FOR AUTOIMMUNE DISORDERS | |
| EP1622608A4 (en) | Compositions and methods for treating cancer | |
| BRPI0607809A2 (en) | use of a composition comprising nanoparticles, composition and kit | |
| BRPI0207961B8 (en) | use of epothilone and capecitabine analogues to manufacture medicine to treat solid cancerous tumors and kit comprising said compounds. | |
| CO6300964A2 (en) | A PHARMACEUTICAL COMPOSITION THAT INCLUDES A COMBINATION OF A CHEMOTHERAPEUTIC AGENT AND AN ANTIGLIPICAN ANTIBODY 3 | |
| AR023616A1 (en) | COMBINED PREPARATIONS UNDERSTANDING ANTHRACICLINE DERIVATIVES | |
| GT200000194A (en) | COMBINATION CHEMOTHERAPY. | |
| BRPI0511475A (en) | combination, pharmaceutical composition, use of a combination, and method for treating cancer | |
| AR040792A1 (en) | THERAPEUTIC COMBINATIONS OF ERB B QUINASA INHIBITORS AND ANTINEOPLASIC THERAPIES | |
| ATE509630T1 (en) | PANCREAS CANCER TREATMENT WITH NA+/K+-ATPASE INHIBITORS | |
| EP1503748A4 (en) | Drugs for mitigating taxane-induced neurotoxicity |